Bayer Leads Series A in Robigo, Betting on Engineered Microbes for Crop Protection

If it holds up in the field, Robigo's lead soybean product matches commercial fungicides at half the cost. Its pipeline moves from design to field data in just 20 months, a cycle time that promises more where that came from.

Robigo has raised a Series A led by Leaps by Bayer, with participation from Illumina Ventures, SVG Thrive, Congruent Ventures and Endeavor8. The Cambridge, Massachusetts company engineers living microbes that manufacture crop protection compounds directly on the plant. Its lead soybean product matches the performance of commercial fungicides at half the cost.

Live biologics have been marketed as agriculture's next frontier since the early 2000s, but farmers have largely ignored them. Living products behave differently across soil types, seasons and application windows in ways that synthetic molecules do not, and farmers end up choosing a fungicide that works every year over a biologic that works in some years. Robigo went looking for the shape of that gap in California's Central Coast, where much of the country's fresh produce is grown.

"We spoke with dozens of growers and ag researchers across specialty crops. What struck us was how limited the standard toolkit is for soil-borne pathogens like Fusarium," said Dr. Andee Wallace, Founder and CEO of Robigo.

"Growers rely on breeding for resistance, which takes more than 10 years, and crop rotation, which is often impossible during peak demand. For strawberries, that also means fumigants costing $3,000 to $5,000 per application that are both expensive and toxic. With disease resistance on the rise, it's clear growers need better tools."

Robigo's answer is to stop treating microbes as active ingredients and instead as the chemical factory. Its ARGO platform designs active ingredients computationally, using modes of action that silence essential genes in the target pathogen. Those compounds are then loaded into a microbe that is applied once and produces them continuously, at the root zone, for the length of the season. Nothing about the farmer's practice changes.

"Most biopesticides are built around whichever microbe happens to naturally produce a pesticidal compound, which means the microbe and the compound come as a package deal. Robigo's ARGO platform breaks that link," Wallace said. "We choose microbial chassis independently, optimizing for microbes that are cheap, shelf stable, easy to apply, and form robust relationships with different crops, then engineer them to produce computationally designed bioactives that are precise and effective in controlling the pest or disease."

"Unlike other sprayed products, which degrade quickly in the field and require repeat applications, our engineered microbes act as living biomanufacturing systems," she said. "They colonize a particular plant niche and produce bioactives directly in the field, giving growers season-long protection from a single application."

The lead program targets Sudden Death Syndrome in soybean, a soil-borne fungal disease that costs United States farmers an estimated $200 to $500 million a year. Robigo is aiming for a 2028 launch. A second program goes after fusarium wilt, currently the top disease problem for lettuce and berry farmers, where field results showed a threefold yield increase over untreated controls. That product is targeted for 2029.

The number that will draw the most scrutiny is neither of those. Robigo says ARGO takes a product from computational design through microbe engineering, lead validation and field testing in under 20 months, against an industry norm of three to five years. The step it compressed hardest was discovery through on-field validation.

"Our differentiated ARGO platform lets us screen a smaller, computationally pre-vetted set of microbes instead of the traditional approach of screening libraries of thousands or hundreds of thousands of strains," Wallace said. "Compressing this timeline also required our team executing at an exceptionally high level, and we're proud of that."

She does not oversell what that timeline has proven.

"That said, we're still early. We need to validate this performance across additional years of field trials, regions, and soil types, and there's plenty of work ahead."

For Leaps, the investment sits squarely inside two of its ten stated challenges, preventing crop and food loss and reducing the environmental impact of agriculture. The unit has put more than $2.1 billion into more than 65 companies since 2015, with an agricultural portfolio that includes Pivot Bio, Andes and Pairwise. What separates Robigo is that it points directly at a market Bayer's own crop science business sells into, and Robigo says the pipeline expansion addresses a $10 billion market opportunity across broadacre crops.

"This investment reflects real conviction in our platform from one of the most established names in crop protection. Beyond the capital, Bayer brings deep experience navigating registration, market access, and global scale, and we expect to draw on that expertise as we grow," Wallace said. "At the same time, we're building a broad set of commercial relationships across the industry, so each product in our pipeline can find the partner and pathway that fits it best."

"The scalability of the ARGO platform is what sets Robigo apart," said Dr. Juergen Eckhardt, EVP and Head of Leaps by Bayer. "They are not just developing a single product but rather building an engine that can rapidly address diverse soil-borne pathogens across broadacre crops."

Several things remain unresolved. Engineered live microbes released at field scale face a regulatory path that purely chemical products do not, and a 2028 soybean launch leaves limited room for the multi-season data Wallace says she still needs. Robigo has been building toward this point for over two years, winning SVG Ventures' THRIVE Global X program in January 2025 and $1.25 million in NSF Phase II SBIR funding that September. 

But if the 20 month cycle is real, the soybean product is the start of a crop medicine engine that can be pointed at a long list of diseases and crops.

"If ARGO performs as we intend, growers will have far more peace of mind heading into planting,“ explains Wallace. “The pests and pathogens that kept them up at night a decade ago will be managed affordably, without breaking the bank. And they'll be doing it with biological products that improve soil biodiversity and health over time, benefiting their land for generations to come."